Table 1.
Clinical and laboratory features of demyelinating and axonal groups
| All Cases | Electrophysiological subtypes | p (axonal/demyelinating groups) | ||
|---|---|---|---|---|
| Demyelinating | Axonal | |||
| Age (year) | 6.8±4.2 y | 7.5±4.2 y | 6.3±4.3 y | NS |
| M/F | 1.3 | 1.0 | 1.7 | NS |
| Duration of weakness (days) | 7.7±7.8 | 7.3±6.8 | 8.2±8.7 | NS |
| Duration of hospitalization (days) | 15±19.6 | 13.4±8.4 | 17.0±23 | NS |
| Antecedent infection (%) | 64.0 | 66.7 | 61.3 | NS |
| Distribution of weakness % of cases | <0.001 | |||
| Flaccid paresis | 52.8 | 54.2 | 41.5 | |
| Tetraparesis | 32 | 32.5 | 40.2 | |
| Tetraparesis + bulbar | 15.2 | 13.3 | 18.3 | |
| Sensory signs% | 25 | 25.3 | 17.3 | NS |
| Sphincter involvement% | 2.6 | 3.6 | 1.2 | NS |
| Cranial nerve involvement% | 15.7 | 18.1 | 20.3 | NS |
| Ventilation requirement% | 9.7 | 9.5 | 12.7 | NS |
| CSF protein mg/dl | 95.2±63.6 | 94.0±59.0 | 94.2±61.7 | NS |
| Treatment | NS | |||
| No treatment | 24.1 | 22.6 | 26.8 | |
| IVIg | 61.2 | 57.1 | 57.3 | |
| Plasmapheresis | 1.3 | 1.2 | 1.2 | |
| Steroid | 0.9 | 1.2 | 1.2 | |
| IVIg+Plasmapheresis | 10.8 | 15.5 | 13.4 | |
| IVIG+steroid | 1.7 | 2.4 | - | |
| Median (interquartile range) clinical score at | ||||
| admission | 4 (3–4) | 4 (3–4) | 4 (4–4) | p=0.022 |
| discharge | 3 (2–4) | 3 (2–3) | 3 (2–4) | NS |
| 1 month | 1 (0–3) | 0 (0–1) | 1 (0–3) | NS |
| 3 months | 1 (0–2) | 1 (0–1) | 1 (0–2.5) | NS |
| 6 months | 0 (0–1) | 0 (0–0.5) | 0 (0–1) | NS |
| 12 months | 0 (0–1) | 0 (0–1) | 0 (0–1) | NS |